Geffen Kleinstern, Nicholas J Boddicker, Daniel R O'Brien, Cristine Allmer, Kari G Rabe, Aaron D Norman, Rosalie Griffin, Huihuang Yan, Tao Ma, Timothy G Call, Laura Bruins, Sochilt Brown, Cecilia Bonolo de Campos, Curtis A Hanson, Jose F Leis, Wei Ding, Celine M Vachon, Neil E Kay, Christopher C Oakes, Alexander Parker, Danielle M Brander, J Brice Weinberg, Richard R Furman, Tait D Shanafelt, James R Cerhan, Sameer A Parikh, Esteban Braggio, Susan L Slager
HCMBL is a precursor condition to chronic lymphocytic leukemia (CLL). We have shown that among individuals with HCMBL the CLL-International Prognostic Index (CLL-IPI) is prognostic for time-to-first therapy (TTFT). Little is known about the prognostic impact of somatically mutated genes among individuals with HCMBL. We sequenced DNA from 371 HCMBL individuals using a targeted sequencing panel of 59 recurrently mutated genes in CLL to identify high-impact mutations. We compared the sequencing results to that of our treatment-naïve CLL cohort(N=855) and employed Cox regression to estimate hazard ratios and 95% confidence intervals (CI) for associations with TTFT...
February 15, 2024: Blood Advances